Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Overview
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Companies Involved in Therapeutics Development
Blade Therapeutics Inc
Boehringer Ingelheim Intertiol GmbH
Eli Lilly and Co
Galapagos NV
iOnctura SA
LegoChem Biosciences Inc
Ono Pharmaceutical Co Ltd
PharmAkea Therapeutics Inc
Ribomic Inc
Sansho Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
X-Rx Inc
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Drug Profiles
2-CCPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBT-877 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLD-0409 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLPG-1690 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IOA-289 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-8430506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAT-048 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ATX and EGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestil Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Autotaxin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Autotaxin for Idiopathic Pulmory Fibrosis and Metastatic Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Autotaxin for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Autotaxin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJC-0265 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJC-0316 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-165 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Dormant Products
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Product Development Milestones
Featured News & Press Releases
Dec 05, 2019: Galapagos completes recruitment of NOVESA trial in systemic sclerosis
Sep 29, 2019: Bridge Biotherapeutics presents positive results from phase 1 clinical study of BBT-877 for Idiopathic Pulmory Fibrosis (IPF) treatments at the ERS Intertiol Congress 2019
May 20, 2019: Bridge Biotherapeutics announces data presentation from first-in-human study of BBT-877 for idiopathic pulmory fibrosis
Jan 24, 2019: X-Rx announces FDA acceptance of IND application for X-165
Jan 16, 2019: Bridge Biotherapeutics announces FDA Orphan Drug Desigtion for BBT-877 in idiopathic pulmory fibrosis (IPF)
Jan 07, 2019: Galapagos starts Phase IIa trial of GLPG1690 for systemic sclerosis
Dec 17, 2018: Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmory Fibrosis (IPF)
Dec 17, 2018: Bridge Biotherapeutics announces FDA clearance of IND for its BBT-877, an autotaxin inhibitor for IPF
Nov 18, 2018: Bridge Biotherapeutics files investigatiol new drug application for BBT-877, an autotaxin inhibitor for idiopathic pulmory fibrosis
Aug 22, 2018: Bridge Biotherapeutics presented preclinical study results on BBT-877, an autotaxin inhibitor at the IPF Summit 2018
May 20, 2018: GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
Apr 12, 2018: Galapagos announces ISABELA Phase 3 program in IPF
Aug 09, 2017: GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial
Sep 06, 2016: Orphan Drug Desigtion in European Union for GLPG1690 in idiopathic pulmory fibrosis
Apr 06, 2016: Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmory fibrosis patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Blade Therapeutics Inc, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Galapagos NV, H2 2019
Pipeline by iOnctura SA, H2 2019
Pipeline by LegoChem Biosciences Inc, H2 2019
Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Pipeline by PharmAkea Therapeutics Inc, H2 2019
Pipeline by Ribomic Inc, H2 2019
Pipeline by Sansho Co Ltd, H2 2019
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2019
Pipeline by X-Rx Inc, H2 2019
Dormant Projects, H2 2019